NASDAQ:PCSA Processa Pharmaceuticals (PCSA) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free PCSA Stock Alerts $2.43 +0.81 (+50.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$2.08▼$2.6850-Day Range$1.52▼$2.9952-Week Range$1.40▼$18.00Volume77.07 million shsAverage Volume2.28 million shsMarket Capitalization$6.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Processa Pharmaceuticals alerts: Email Address Processa Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish8.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingAcquiring Shares$105,895 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.77 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Processa Pharmaceuticals. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.28% of the float of Processa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverProcessa Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Processa Pharmaceuticals has recently increased by 429.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProcessa Pharmaceuticals does not currently pay a dividend.Dividend GrowthProcessa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PCSA. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Processa Pharmaceuticals this week, compared to 1 article on an average week.Search Interest15 people have searched for PCSA on MarketBeat in the last 30 days. This is an increase of 114% compared to the previous 30 days.MarketBeat Follows4 people have added Processa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Processa Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $105,895.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.20% of the stock of Processa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.93% of the stock of Processa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Processa Pharmaceuticals is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Processa Pharmaceuticals is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProcessa Pharmaceuticals has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Processa Pharmaceuticals Stock (NASDAQ:PCSA)Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.Read More PCSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCSA Stock News HeadlinesApril 11, 2024 | msn.comU.S. shares lower at close of trade; Dow Jones Industrial Average down 1.09%April 11, 2024 | finance.yahoo.comProcessa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b TrialApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 7, 2024 | finance.yahoo.comInsider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40kMarch 28, 2024 | nz.finance.yahoo.comEva Mendes says she had 'non-verbal agreement' with Ryan Gosling to be a stay-at-home momMarch 28, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 25, 2024 | globenewswire.comProcessa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual MeetingFebruary 24, 2024 | msn.comProcessa Pharmaceuticals (PCSA) Price Target Increased by 1900.00% to 81.60April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.February 21, 2024 | finance.yahoo.comProcessa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 21, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 14, 2024 | finance.yahoo.comProcessa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual ConferenceFebruary 14, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual ConferenceFebruary 6, 2024 | markets.businessinsider.comProcessa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleFebruary 6, 2024 | investing.comProcessa Pharmaceuticals Inc (PCSA)February 1, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Closing of $7.0 Million Public OfferingFebruary 1, 2024 | msn.comProcessa Pharmaceuticals Announces Offering Pricing DetailsJanuary 27, 2024 | marketwatch.comProcessa Pharmaceuticals Shares Drop 24% After Pricing OfferingJanuary 26, 2024 | msn.comProcessa Pharmaceuticals prices discounted stock and warrants offering to raise $7MJanuary 26, 2024 | msn.comWhat's Going On With Anti Cancer Focused Processa Pharmaceuticals Stock Today?January 26, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Pricing of $7.0 Million Public OfferingJanuary 25, 2024 | marketwatch.comProcessa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer TreatmentJanuary 25, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 DosesJanuary 20, 2024 | msn.comProcessa Pharmaceuticals Expands NGC-Cap Cancer ProgramJanuary 19, 2024 | finanznachrichten.deProcessa Pharmaceuticals, Inc.: Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast CancerJanuary 19, 2024 | msn.comWhy Processa Pharmaceuticals (PCSA) Stock Is SkyrocketingJanuary 19, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast CancerSee More Headlines Receive PCSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Processa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PCSA CUSIPN/A CIK1533743 Webwww.processapharmaceuticals.com Phone(443) 776-3133Fax443-288-4420Employees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-141.42% Return on Assets-122.25% Debt Debt-to-Equity RatioN/A Current Ratio7.70 Quick Ratio7.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.05 per share Price / Book0.56Miscellaneous Outstanding Shares2,860,000Free Float2,222,000Market Cap$6.44 million OptionableNot Optionable Beta0.53 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. George K. Ng Esq. (Age 50)J.D., Chief Executive Officer Comp: $400.27kDr. David Young Ph.D. (Age 71)Pharm.D., Co-Founder, President of Research and Development & Director Comp: $160.2kDr. Sian E. Bigora Ph.D. (Age 64)Pharm.D., Co-Founder and Chief Development & Regulatory Officer Comp: $184.87kMr. James H. Stanker (Age 66)Chief Financial Officer Comp: $160.2kMr. Patrick Lin (Age 59)Co-Founder, Chief Business & Strategy Officer Comp: $117.15kMs. Wendy J. Guy (Age 60)Co-Founder, Chief Administrative Officer & Corporate Secretary Comp: $94.19kMore ExecutivesKey CompetitorsLongeveronNASDAQ:LGVNChina PharmaNYSE:CPHIExicureNASDAQ:XCURSeelos TherapeuticsNASDAQ:SEELPetros PharmaceuticalsNASDAQ:PTPIView All CompetitorsInsiders & InstitutionsDavid YoungBought 21,000 shares on 2/7/2024Total: $51,450.00 ($2.45/share)Spinnaker TrustBought 76,865 shares on 2/2/2024Ownership: 6.249%Patrick LinBought 2,500 shares on 1/31/2024Total: $5,925.00 ($2.37/share)Justin W YorkeBought 8,000 shares on 1/30/2024Total: $21,520.00 ($2.69/share)George K NgBought 10,000 shares on 1/30/2024Total: $27,000.00 ($2.70/share)View All Insider TransactionsView All Institutional Transactions PCSA Stock Analysis - Frequently Asked Questions Should I buy or sell Processa Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Processa Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PCSA shares. View PCSA analyst ratings or view top-rated stocks. How have PCSA shares performed in 2024? Processa Pharmaceuticals' stock was trading at $6.6920 at the beginning of 2024. Since then, PCSA stock has decreased by 63.7% and is now trading at $2.43. View the best growth stocks for 2024 here. Are investors shorting Processa Pharmaceuticals? Processa Pharmaceuticals saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 189,600 shares, an increase of 429.6% from the March 31st total of 35,800 shares. Based on an average daily volume of 1,560,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 8.3% of the company's stock are sold short. View Processa Pharmaceuticals' Short Interest. When is Processa Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PCSA earnings forecast. How were Processa Pharmaceuticals' earnings last quarter? Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) issued its quarterly earnings results on Friday, March, 29th. The company reported ($0.24) EPS for the quarter. When did Processa Pharmaceuticals' stock split? Processa Pharmaceuticals's stock reverse split before market open on Monday, January 22nd 2024. The 1-20 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Processa Pharmaceuticals? Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PCSA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Processa Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
